IDH1/2-mutant clonal hematopoiesis: A novel driver of autoinflammatory disease
Griffen Mustion(Saint Louis University), Kelly L. Bolton(Washington University in St. Louis), Alejandro Marinos Velarde(The University of Texas Southwestern Medical Center), Ryan Monahan, Matthew Schwede(Stanford University), Giulia E.M. Petrone(Saint Louis University), Hetty E. Carraway(Cleveland Clinic), Matthew J. Walter(MACOM (United States)), Stephen S. Chung(Memorial Sloan Kettering Cancer Center), Hannah Mitchell(Saint Louis University), David A. Sallman(Moffitt Cancer Center), Luke B. Fletcher(Willamette Valley Cancer Institute and Research Center), Flore Castellan(New York University), Hannah Hartman(Saint Louis University), Jon C. Cole(Aurora College), Akriti Jain(Cleveland Clinic), Abhay Singh(Cleveland Clinic), Jennifer Yannucci(Savannah Law School), Kimberly B. Johansson, Rosalyn Marar(WinnMed), David B. Beck(Center for Human Genetics), Devendra Hiwase(Australasian Leukaemia and Lymphoma Group), Namrata S. Chandhok(Sylvester Comprehensive Cancer Center), Yael Kusne(WinnMed), Rickey Myhand(Covenant Health), Eytan M. Stein(Memorial Sloan Kettering Cancer Center), Tian Yi Zhang(Stanford University), Mrinal M. Patnaik(Mayo Clinic), Alexander Coltoff(Columbia University Irving Medical Center), Curtis A. Lachowiez(Oregon Health & Science University), Yazan F. Madanat(The University of Texas Southwestern Medical Center), Geoffrey L. Uy(Memorial Sloan Kettering Cancer Center), Jane Churpek(University of Wisconsin–Madison), Tibor Kovacsovics(Hôpital Edouard Herriot), Kyra Ddungu(Saint Louis University), Karen Vandervort(Saint Louis University), Kiran Vij(Washington University in St. Louis), Maria Stoentcheva(Saint Louis University), Amber Afzal(Unknown)
Cited by 0
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783